A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Suthesh Sivapalaratnam, Steve Austin, Ulrike Lorch, Thomas York, Andrew Want, Ashley Gosnell, Prafull S. Gandhi, Henrik Østergaard, Erik Bjornson, Tara O'Meara, Benny Sorensen, Roger E.G. Schutgens, Catherine Rea

Exciting findings from a Phase 1/2 first-in-human study on HMB-001 for Glanzmann thrombasthenia have been published in Blood (2023).

Download Full Paper Here
Back to news

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

April 30, 2024
Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.
Read more

Announcement of Jorg Becoming President Elect

April 22, 2024
Richmond Pharmacology announces CEO Dr. Jorg Taubel's appointment as President Elect of Germany's AGAH, where he will enhance early-phase clinical research over a six-year term.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event
© 2024 Richmond Pharmacology - all rights reserved
Disclaimer
|
Sitemap
|
Privacy Policy
|
Report A Concern
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept